From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer

Seminars in Oncology

Volumn 38, Issue 4, 2011, Pages 521-532

  De Gramont, Aimery ^a,b,c   De Gramont, Armand ^a,c   Chibaudel, Benoist ^a   Bachet, Jean Baptiste ^a   Larsen, Annette K ^c   Tournigand, Christophe ^a,c   Louvet, Christophe ^c,d   André, Thierry ^a,b,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; MOLECULAR MARKER; OXALIPLATIN; VASCULOTROPIN;

ADJUVANT THERAPY; ADVANCED CANCER; AGING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COLON CANCER; DIARRHEA; DIGESTIVE SYSTEM HEMORRHAGE; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG TARGETING; FOLLOW UP; GENE MUTATION; HUMAN; ISCHEMIA; LIFE EXPECTANCY; LYMPH NODE METASTASIS; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 79961016292     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.05.006     Document Type: Article

References (74)

1. http://globocan.iarc.fr/summary-table-pop.asp?selection=219900&title= World&sex=0&type=0&window=1&sort=0&submit=%A0Execute%A0.
2. American Cancer Society. Cancer facts & figures 2009. Atlanta: American Cancer Society; 2009. Available at: www.cancer.org/downloads/STT/ 500809web.pdf.
3. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. The Multicenter International Study of Oxaliplatin/5- Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. N Engl J Med. 2004;350:2343-51.
4. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198-204. (Pubitemid 46954643)
5. Chou JF, Row D, Gonen M, Liu YH, Schrag D, Weiser MR. Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study. Cancer. 2010;116:2560-70.
6. American Joint Committee on Cancer. AJCC cancer staging manual. 7th edition. New York: Springer; 2010.
7. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352-8. (Pubitemid 20042739)
8. International Multicentre Pooled Analysis of Colorectal Cancer Trials (IMPACT). Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345:939-44.
9. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999;17:3553-9. (Pubitemid 29517927)
10. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23:8664-70. (Pubitemid 46211509)
11. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in highrisk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23:8671-8. (Pubitemid 46211510)
12. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345: 1091-7.
13. André T, Colin P, Louvet C, et al. A semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol. 2003;21:2896-903. (Pubitemid 46621839)
14. André T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 2007;20:3732-8. (Pubitemid 47372615)
15. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696-704. (Pubitemid 41007824)
16. Sakamoto J, Ohashi Y, Hamada C, Buyse M, Burzykowski T, Piedbois P. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol. 2004;22:484-92. (Pubitemid 41079778)
17. Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006;24:2059-64. (Pubitemid 46622115)
18. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18:2938-47. (Pubitemid 30644117)
19. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343:905-14.
20. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355: 1041-7. (Pubitemid 30162806)
21. Haller DG, Cassidy J, Tabernero J, et al. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): no impact of age on disease-free survival (DFS) [abstract 284]. 2010 Gastrointestinal Cancers Symposium. Orlando, FL; January 22-24, 2010.
22. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109-16.
23. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-37. (Pubitemid 41095086)
24. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25:3456-61. (Pubitemid 47310883)
25. Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/ folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol. 2009;20:1964-70.
26. Van Cutsem, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/ leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27:3117-25.
27. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350: 2335-42. (Pubitemid 38702844)
28. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in firstline metastatic colorectal cancer. Results of a randomized phase II trial. J Clin Oncol. 2005;23:3697-705.
29. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol. 2007;25: 1539-44. (Pubitemid 46733080)
30. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-9.
31. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339:58-61. (Pubitemid 19115892)
32. Allegra C, Yothers G, O'Connell M, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009;27:3385-90.
33. Wolmark N, Yothers G, O'Connell MJ, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08 [abstract LBA-4]. J Clin Oncol. 2009;27 18s:793s.
34. Loges S, Mazzone M, Hohensinner P, et al. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell. 2009;15:167-70.
35. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15: 232-9.
36. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-31.
37. Hoff P, Clarke S, Cunnigham D, et al. A three-arm phase III randomized trial of FOLFOX-4 vs. FOLFOX-4 plus bevacizumab vs. XELOX plus bevacizumab in the adjuvant treatment of patients with stage III or high-risk stage II colon cancer: results of the interim safety analysis of the AVANT trial. Eur J Cancer Suppl. 2009;7:324.
38. http://www.roche.com/investors/ir-update/inv-update-2010-09-18b.html.
39. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374-9. (Pubitemid 351171687)
40. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-17.
41. Bokemeyer C, Bondarenko I, Hartmann J, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2008;27:663-71.
42. Adams RA, Meade AM, Seymour MT, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011, Jun 3. [Epub ahead of print].
43. Alberts SR, Sargent DJ, Smyrrk TC, et al. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: results from NCCTG intergroup phase III trial NO147. J Clin Oncol. 2010:28 18S:959s.
44. Goldberg RM, Sargent DJ, Thibodeau N, et al. Adjuvant mFOLFOX6 plus or minus cetuximab in patients with KRAS mutant resected stage III colon cancer: NCCTG intergroup phase III trial NO147. J Clin Oncol. 2010:28 15S:262s.
45. Bachet JB, Laurent-Puig P, de Gramont A, André T. Microsatellite status and adjuvant chemotherapy in patients with stage II colon cancer. Curr Colorectal Cancer Rep. In press.
46. Johnson PM, Porter GA, Ricciardi R, Baxter NN. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol. 2006;24:3570-5. (Pubitemid 46630528)
47. Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol. 2005;23:8706-12. (Pubitemid 46211514)
48. Roth AD, Tejpar S, Yan P, et al. Molecular markers in colon cancer have a stage specific prognostic value. Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol. 2009;27 15S:4002.
49. Roth AD, Tejpar S, Delorenzi M, et al, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010:28: 466-74.
50. Watanabe T, WU TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344:1196-206. (Pubitemid 32319494)
51. Zaanan A, Cuilliere-Dartigues P, Guilloux A, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 2010;21:772-80.
52. Gangadhar T, Schilsky R. Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol. 2010;7:318-25.
53. Deschoolmeester V, Baay M, Specenier O, Lardon F, Vermorken JB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist. 2010;15:699-731.
54. Pallante PL, Terracciano L, Carafa V, et al. The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur J Cancer. 2010;46:2304-13.
55. Kerr D, Gray R, Quirke P, et al. A quantitative multi-gene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in 4 large studies and results of the independent, prospectively-designed QUASAR validation study. J Clin Oncol. 2009;27 15S: 4000.
56. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and surrogate end points: the chal- lenge of statistical validation. Nat Rev Clin Oncol. 2010;7:309-17.
57. http://data.un.org/Data.aspx?d=GenderStat&f=inID%3A36.
58. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/ leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006; 24:4085-91. (Pubitemid 46622283)
59. Jackson McCleary NA, Meyerhardt J, Green E, et al. Impact of older age on the efficacy of newer adjuvant therapies in >12500 patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol. 2009;27 15S:4010.
60. Tournigand C, André T, Bacher JB, et al. FOLFOX4 as adjuvant therapy in elderly patients with colon cancer: subgroup analysis of the MOSAIC trial. J Clin Oncol. 2010;28 15S:266s.
61. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-45. (Pubitemid 38944402)
62. de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology. 2005;69 suppl 3:46-56.
63. Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008;27:3944-56. (Pubitemid 351913636)
64. Jain A, Penuel E, Mink S, et al. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res. 2010;70:1989-99.
65. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592-603.
66. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell. 2009;15:167-70.
67. Cacheux W, Boisserie T, Staudacher L, et al. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol. 2008;19:1659-61.
68. Rasheed ZA, Rubin EH. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene. 2003;22: 7296-304. (Pubitemid 37487161)
69. Sinicrope FA, Rego RL, Foster NR, et al. Proapoptotic Bad and Bid protein expression predict survival in stage II and III colon cancers. Clin Cancer Res. 2008;14:4128-33.
70. Watanabe T. Ongoing colorectal cancer adjuvant trials in Japan. Curr Colorectal Cancer Rep. 2010;6:168-174.
71. Amit I, Wides R, Yarden Y. Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol. 2007; 3:151.
72. Sargent DJ, Patiyil S, Yothers G, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT group. J Clin Oncol. 2007;25:4569-74. (Pubitemid 350035314)
73. http://www.adjuvantonline.com/index.jsp.
74. Love N, Bylynd C, Meropol NJ, et al. How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors. J Clin Oncol. 2007;25 18S:168s.